more on SLN Silence Therapeutics: Merck KGaA to Acquire Company for $1.3 Billion in Cash at $20 Per ADS, a 130% Premium ? • All-cash deal values Silence at ~$1.3B in equity value and $1.1B in enterprise value, representing an 82% premium to its 30-day VWAP. • Acquisition strengthens Merck KGaA's rare disease pipeline, including Silence's siRNA candidate Divesiran following positive Phase 2 data in polycythemia vera. • Transaction unanimously approved by Silence's board, with closing expected in Q1 2027, subject to shareholder and regulatory approvals. 19-OCT-2026 08:12 AM ET